Tania Nikolcheva, Gavin Giovannoni and Tharick Pascoal on the Special issue in Neurology

Hi, everyone.

It's a pleasure to be here.

I am Tania Nikolcheva.

I'm a physician scientist and a drug developer with experience across stages of development from early to late.

And I lead the clinical development of prazenezumab, which we'll discuss today.

It's an anti-synuclein antibody.

So we presented here the results of the Padova trial.

This is a large phase 2b study in individuals with early stage Parkinson's disease.

And what was very important is that they were being treated with their standard of care symptomatic medication.

So as opposed to previous trials where we went into treatment.

Well, this study didn't meet its primary endpoint.

We didn't quite make the cutoff of 0.05. We observed highly consistent signals of clinical activity across the primary, secondary endpoints, and some of the exploratory.

We did see also biomarker data supporting a reduced loss of neuromelanin and iron, and this suggests potentially an impact on dopaminergic neuron loss.

So on top of the favorable safety and tolerability profile, this is a molecule that was worth pursuing and we're now taking it in phase three, taking the learnings from this large study ahead.

Fantastic.

Thank you so much.

And if we can go now to Gavin, please.

Hi, yes, I'm Gavin Giovannoni.

I'm a neurologist and I specialize in multiple sclerosis and I'm based in East End of London at the Royal London Hospital.

And I'm going to be discussing two really phase three trials.

First one is really important in terms of the field.

We were testing ocrelizumab in primary progressive MS.

And this is the first trial that's really extended recruitment into people that are wheelchair users.

And it was a positive trial.

And the second study was, there's actually two studies presented in one.